{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:23Z","timestamp":1791464243734,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ygyno.2024.05.008","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:37:49Z","timestamp":1716493069000},"page":"170-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status"],"prefix":"10.1016","volume":"187","author":[{"given":"Claudia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina M.","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana I.","family":"Apostol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierandrea","family":"De Iaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Angela","family":"Camnasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Moubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2024.05.008_bb0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2021.09.004","article-title":"Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1\/2-mutation - real life data","volume":"163","author":"Ataseven","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.008_bb0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13048-019-0511-7","article-title":"Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer","volume":"12","author":"Kim","year":"2019","journal-title":"J. Ovarian Res."},{"issue":"21","key":"10.1016\/j.ygyno.2024.05.008_bb0015","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian Cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2024.05.008_bb0020","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.008_bb0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology\/Gynecologic Oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"46","key":"10.1016\/j.ygyno.2024.05.008_bb0030","doi-asserted-by":"crossref","first-page":"101173","DOI":"10.1016\/j.gore.2023.101173","article-title":"Recurrence rate in early-stage epithelial ovarian cancer: is there a role for upfront maintenance with PARP inhibitors in stages I and II?","volume":"31","author":"Levine","year":"2023","journal-title":"Gynecol Oncol Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.05.008_bb0035","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.008_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.113","article-title":"International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","author":"Trimbos","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.008_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","volume":"95","author":"Trimbos","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.008_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/95.2.125","article-title":"International collaborative ovarian neoplasm (ICON) collaborators. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer","volume":"95","author":"Colombo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.008_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2024.05.008_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"23","key":"10.1016\/j.ygyno.2024.05.008_bb0065","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"DESKTOP III investigators. Randomized trial of Cytoreductive surgery for relapsed ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2024.05.008_bb0070","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA mutation status to personalize Management of Recurrent Ovarian Cancer: a multicenter study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.008_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1245\/s10434-022-12459-3","volume":"30","author":"Glajzer","year":"2023","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.05.008_bb0080","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.008_bb0085","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ijgc-2022-004190","article-title":"Myeloid neoplasms post PARP inhibitors for ovarian cancer","volume":"33","author":"Caruso","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"30","key":"10.1016\/j.ygyno.2024.05.008_bb0090","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance Olaparib for patients with newly diagnosed advanced ovarian Cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:42:11Z","timestamp":1745329331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824002208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":18,"alternative-id":["S0090825824002208"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}